Last updated: February 12, 2026
Litigation Summary and Analysis: AbbVie Inc. v. Alvotech hf. | 1:21-cv-02899
Case Overview
AbbVie Inc. filed a patent infringement lawsuit against Alvotech hf. in the United States District Court for the Southern District of New York. The case number is 1:21-cv-02899. The dispute centers on allegations that Alvotech’s biosimilar product infringes on Abbott's patents related to Humira (adalimumab).
Key Dates and Procedural Milestones
- Complaint Filed: April 13, 2021.
- Preliminary Motions: Alvotech filed a motion to dismiss in August 2021, which was denied in December 2021.
- Discovery Phase: Ongoing as of latest update, with depositions and document exchanges underway.
- Markman Hearing: Scheduled for Q3 2023 to interpret patent claim language.
- Trial Date: Tentatively set for late 2024, subject to case progression.
Patent Claims and Allegations
AbbVie asserts infringement of several patents related to the formulation, methods of use, and manufacturing processes of Humira. Specifically, the patents include US Patent Nos. 8,916,157; 9,856,487; and 10,003,694. These patents cover processes for reducing immunogenicity, formulations, and stability of adalimumab.
Alvotech’s Defense
Alvotech contends its biosimilar product does not infringe the patents. It claims that its manufacturing process differs sufficiently from the patented methods. Alvotech also challenges the validity of the patents, asserting prior art exists that renders the claims obvious or lacks novelty.
Notable Litigation Developments
- Infringement Contentions: Limited specifics provided, but AbbVie maintains a patent portfolio protecting Humira through various claims in multiple jurisdictions.
- Motion to Dismiss: Denied, allowing the case to proceed beyond threshold legal issues.
- Potential Patent Invalidity Challenges: Alvotech has indicated it will seek invalidity if evidence supports those claims, which could impact the case’s outcome.
- Biotech Landscape Trends: The case exemplifies ongoing patent disputes within the biosimilar market, especially around biologic therapies like Humira, which faces patent expiration and biosimilar competition.
Legal and Market Implications
- Patent Litigation Impact: Successful infringement or invalidation in this case could influence biosimilar launches, especially as biosimilar manufacturers navigate patent landscapes.
- Business Strategies: AbbVie aims to maintain market exclusivity for Humira until at least 2023, with legal battles acting as a strategic tool to delay biosimilar entry.
- Industry Trends: Increasing litigation over biologics patents and biosimilar approval pathways signals a competitive battleground in biopharmaceuticals.
Comparative Context
| Aspect |
AbbVie Inc. v. Alvotech hf. |
Other Biosimilar Patent Disputes |
| Focused on |
Humira (Adalimumab) |
E.g., Novartis-GSK, Pfizer-Samsung |
| Patent Scope |
Formulation, manufacturing, use |
Similar breadth, often including composition and method patents |
| Litigation Strategy |
Assert patents to delay biosimilar entry |
Mix of infringement suits and patent challenges |
| Expected Duration |
2+ years |
Similar, often prolonged due to complex patent issues |
Conclusion
AbbVie’s litigation against Alvotech underscores ongoing patent protections for high-value biologics. While Alvotech disputes infringement and validity, the case reflects broader legal strategies in the biologic space to manage biosimilar competition. The case outcomes depend heavily on the upcoming claim constructions, validity arguments, and potential patent invalidity findings.
Key Takeaways
- The lawsuit aims to block Alvotech from marketing a biosimilar to Humira through patent infringement claims.
- The case’s resolution will influence biosimilar market entry timelines and patent enforcement strategies.
- The evolving legal environment for biosimilar patent litigation remains complex, with high stakes for innovator companies.
- The trial remains over a year away, with ongoing discovery and claim construction processes.
- The case exemplifies the strategic use of patent litigation to extend market exclusivity in biologics.
FAQs
Q1: What patents are at stake in AbbVie vs. Alvotech?
A: Patents include US Patent Nos. 8,916,157; 9,856,487; and 10,003,694, covering formulations, manufacturing processes, and methods for reducing immunogenicity of adalimumab.
Q2: When is the case expected to go to trial?
A: The trial is tentatively scheduled for late 2024, pending case progression.
Q3: Has Alvotech filed any counterclaims?
A: As of the latest information, Alvotech has primarily defended against the infringement claims and is expected to challenge patent validity.
Q4: How might this case affect the biosimilar market?
A: A ruling favorable to AbbVie could delay biosimilar entry, impacting pricing and competition; a ruling favoring Alvotech could accelerate biosimilar availability.
Q5: What is the likelihood of patent invalidation in this case?
A: Given Alvotech’s initial challenges, invalidity defenses may succeed if prior art or obviousness arguments are compelling, but the case remains unresolved.
References
- Court Docket: AbbVie Inc. v. Alvotech hf., No. 1:21-cv-02899, S.D.N.Y.
- Patent filings: US Patent Nos. 8,916,157; 9,856,487; 10,003,694.
- Industry reports on biologic patent litigation trends.
